Dr Sheldon H Katz, DDS | |
5363 Balboa Blvd, Suite 233, Encino, CA 91316-2805 | |
(818) 788-4424 | |
(818) 788-4426 |
Full Name | Dr Sheldon H Katz |
---|---|
Gender | Male |
Speciality | Oral & Maxillofacial Surgery |
Location | 5363 Balboa Blvd, Encino, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114088721 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223S0112X | Dentist - Oral And Maxillofacial Surgery | D28732 (California) | Primary |
204E00000X | Oral & Maxillofacial Surgery | D28732 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Sheldon H Katz, DDS 5363 Balboa Blvd, Suite 233, Encino, CA 91316-2805 Ph: (818) 788-4424 | Dr Sheldon H Katz, DDS 5363 Balboa Blvd, Suite 233, Encino, CA 91316-2805 Ph: (818) 788-4424 |
News Archive
RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.0 million for the first quarter ended March 31, 2010, compared to net sales of $6.0 million for the same period during 2009, an increase of 16%.
Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.
Officials at the university and the District of Columbia's Health Department confirmed 85 cases of the gastrointestinal illness were diagnosed since Monday. The virus was found in locations including the central Foggy Bottom campus and the Mount Vernon campus in Northwest Washington. Members of the university also reported cases off campus.
Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.
› Verified 9 days ago